InvestorsObserver
×
News Home

Design Therapeutics Inc (DSGN) Stock: What Does the Chart Say Thursday?

Thursday, June 09, 2022 03:42 PM | InvestorsObserver Analysts

Mentioned in this article

Design Therapeutics Inc (DSGN) Stock: What Does the Chart Say Thursday?

Design Therapeutics Inc (DSGN) stock has risen 2.03% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,neutral
Design Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on DSGN!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With DSGN Stock Today?

Design Therapeutics Inc (DSGN) stock is trading at $14.04 as of 3:39 PM on Thursday, Jun 9, a loss of -$0.62, or -4.23% from the previous closing price of $14.66. The stock has traded between $14.00 and $14.80 so far today. Volume today is below average. So far 50,890 shares have traded compared to average volume of 179,565 shares. To see InvestorsObserver's Sentiment Score for Design Therapeutics Inc click here.

More About Design Therapeutics Inc

Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Click Here to get the full Stock Report for Design Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App